Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.

Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK.

Pediatr Blood Cancer. 2011 Feb;56(2):191-201. doi: 10.1002/pbc.22767.

2.

Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.

Clement SC, van Eck-Smit BL, van Trotsenburg AS, Kremer LC, Tytgat GA, van Santen HM.

Pediatr Blood Cancer. 2013 Nov;60(11):1833-8. doi: 10.1002/pbc.24681.

PMID:
23832530
3.
4.

Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.

Picco P, Garaventa A, Claudiani F, Gattorno M, De Bernardi B, Borrone C.

Cancer. 1995 Nov 1;76(9):1662-4.

6.

Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases.

van Santen HM, Tytgat GA, van de Wetering MD, van Eck-Smit BL, Hopman SM, van der Steeg AF, Nieveen van Dijkum EJ, van Trotsenburg AS.

Thyroid. 2012 Jun;22(6):643-6. doi: 10.1089/thy.2011.0464.

PMID:
22524499
7.

Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.

Brans B, Monsieurs M, Laureys G, Kaufman JM, Thierens H, Dierckx RA.

Med Pediatr Oncol. 2002 Jan;38(1):41-6.

PMID:
11835235
8.

Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma.

Clement SC, van Rijn RR, van Eck-Smit BL, van Trotsenburg AS, Caron HN, Tytgat GA, van Santen HM.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):706-15. doi: 10.1007/s00259-014-2967-4.

PMID:
25512056
9.

Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.

Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK.

Cancer. 2011 Sep 15;117(18):4286-93. doi: 10.1002/cncr.25987.

10.

Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, Mosse YP.

Pediatr Blood Cancer. 2011 Dec 15;57(7):1124-9. doi: 10.1002/pbc.23062.

PMID:
21495159
11.

Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).

Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK.

Eur J Cancer. 2015 Nov;51(16):2465-72. doi: 10.1016/j.ejca.2015.07.023.

12.

Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).

Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK.

Pediatr Blood Cancer. 2016 Mar;63(3):436-42. doi: 10.1002/pbc.25816.

PMID:
26506090
13.

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.

J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Erratum in: J Nucl Med. 2016 Jun;57(6):988.

14.

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM.

J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628.

15.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.

PMID:
17369569
16.

Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.

Bleeker G, Schoot RA, Caron HN, de Kraker J, Hoefnagel CA, van Eck BL, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1711-7. doi: 10.1007/s00259-013-2510-z.

17.

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D.

J Clin Oncol. 1998 Jan;16(1):229-36.

PMID:
9440747
18.

Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM.

J Pediatr Hematol Oncol. 2003 Oct;25(10):769-73.

PMID:
14528098
19.

131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma.

Hutchinson RJ, Sisson JC, Shapiro B, Miser JS, Normole D, Shulkin BL, Francis IR, Zasadny K, Carey JE, Johnson JW, et al.

Am J Clin Oncol. 1992 Jun;15(3):226-32.

PMID:
1590275
20.

Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.

Clement SC, Kraal KC, van Eck-Smit BL, van den Bos C, Kremer LC, Tytgat GA, van Santen HM.

J Clin Endocrinol Metab. 2014 Jan;99(1):E112-6. doi: 10.1210/jc.2013-3595.

PMID:
24187404
Items per page

Supplemental Content

Support Center